Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
TREM2 regulates microglial cell activation in response to demyelination in vivo.
Free radicals: properties, sources, targets, and their implication in various diseases.
Further validation of the Multiple Sclerosis Self-Efficacy Scale.
Multiple sclerosis drugs: how much bang for the buck?
Purine-crosslinked injectable chitosan sponges promote oligodendrocyte progenitor cells' attachment and differentiation.
Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease.
Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report.
Does Aquaporin-4-Seronegative Neuromyelitis Optica Exist?
Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.
An initial validation of the Italian Mishel Uncertainty Illness Scale (MUIS) for relapsing remitting multiple sclerosis patients.
Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.
KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis.
Sphingolipids: important players in multiple sclerosis.
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.
Three-dimensional ultra-structures of myelin and the axons in the spinal cord: Application of SEM with the osmium maceration method to the central nervous system in two mouse models.
Potential Beneficial Effects of Marine Peptide on Human Neuron Health.
Iron deposition in the precentral grey matter in patients with multiple sclerosis: A quantitative study using susceptibility-weighted imaging.
NLRP3 Inflammasome and MS/EAE.
Oral BG-12 in multiple sclerosis.
Balkans syndrome: a potential link between multiple sclerosis and hypervaccination.
[A retrospective study of patients with early onset of multiple sclerosis in Omskaya Oblast.]
[Does interferon beta slow the progression of multiple sclerosis? - Long-term effect of IFN-β on progression of physical disability is still not proven].
Multifocal Acquired Demyelinating Sensory and Motor Neuropathy: Unexpected Diagnosis After Ultrasound Imaging for a Humeral Fracture.
Transglutaminase 2 and neuroinflammation.
Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Pages
« first
‹ previous
…
389
390
391
392
393
394
395
396
397
…
next ›
last »